Table 4.
Summary of cost-effectiveness analysis results
| Cost (AU$) | Diagnostic rate | Incremental cost (AU$) | Incremental outcome | ICER (AU$) | |
|---|---|---|---|---|---|
| Adult patients | |||||
| Model 1: Nongenomic investigations | 1830 | 0.08 | |||
| Model 2: Late genomic sequencing (panel+ES) | 5600 | 0.35 | Dominated by model 5 | ||
| Model 3: Late genomic sequencing (ES) | 4070 | 0.35 | Dominated by model 5 | ||
| Model 4: Early genomic sequencing (panel +ES) | 5000 | 0.37 | Dominated by model 5 | ||
| Model 5: Early genomic sequencing (panel only) | 3440 | 0.32 | Dominated by model 5 | ||
| Model 6: Early genomic sequencing (ES) | 3390 | 0.37 | 1560 | 0.29 | 5460 |
| Pediatric patients | |||||
| Model 1: Nongenomic investigations | 6120 | 0.04 | |||
| Model 2: Late genomic sequencing (panel+ES) | 9850 | 0.40 | Dominated by model 5 | ||
| Model 3: Late genomic sequencing (ES) | 8360 | 0.40 | Dominated by model 5 | ||
| Model 4: Early genomic sequencing (panel +ES) | 6470 | 0.42 | Dominated by model 5 | ||
| Model 5: Early genomic sequencing (panel only) | 5230 | 0.33 | Dominated by model 5 | ||
| Model 6: Early genomic sequencing (ES) | 4900 | 0.42 | −1220 | 0.38 | Dominant |
ES, exome sequencing.